Seminars in Nuclear Medicine
Volume 34, Issue 2 , Pages 112-121 , April 2004

2-deoxy-2-[18F]fluoro-d-glucose and alternative radiotracers for positron emission tomography imaging using the human brain as a model

  • Joanna S Fowler

      Affiliations

    • Brookhaven National Laboratory, Upton, NY, USA
    • Corresponding Author InformationAddress reprint requests to: Joanna S. Fowler, PhD, Chemistry Department, Brookhaven National Laboratory, Upton, NY 11973, USA
    • ,
  • Nora D Volkow

      Affiliations

    • National Institute on Drug Abuse, Bethesda, MD, USA
    • ,
  • Gene-Jack Wang

      Affiliations

    • Brookhaven National Laboratory, Upton, NY, USA
    • ,
  • Yu-Shin Ding

      Affiliations

    • Brookhaven National Laboratory, Upton, NY, USA

References 

  1. Reivich M, Kuhl D, Wolf AP, et al.  The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose metabolism in man. Circ Res. 1979;44:127–137
  2. Ido T, Wan C-N, Casella V, et al.  Labeled 2-deoxy-D-glucose analogs, 18F-labeled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-S-glucose. J Label Compounds Radiopharm. 1978;14:171–183
  3. Hamacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of NCA 2-[18F]fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235–238
  4. Fowler JS, Ido T. Initial and subsequent approach for the synthesis of 18FDG. Semin Nucl Med. 2002;32:6–12
  5. Satyamurthy N, Phelps ME, Barrio JR. Electronic generators for the production of positron-emitter labeled radiopharmaceuticals; Where would PET be without them?. Clinical Positron Imaging. 1999;2:233–252
  6. Gambhir SS, Czernin J, Schwimmer J, et al.  A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42:1S–93S
  7. Fowler JS, Volkow ND, Wang G-J, et al.  PET and drug research and development. J Nucl Med. 1999;40:1154–1163
  8. Fowler JS, Ding Y-S, Volkow ND. Radiotracers for positron emission tomography. Sem Nucl Med. 2003;32:14–27
  9. Terry RD, DeTeresa R, Hansen LA. Neocortical cell counts in normal human adult aging. Ann Neurol. 1987;21:530–539
  10. Gomez-Isla T, Price JL, McKeel DW, et al.  Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci. 1996;16:4491–4500
  11. Palmer AM, DeKosky ST. Monoamine neurons in aging and Alzheimer’s disease. J Neural Transm [Gen Sect]. 1993;91:135–159
  12. Volkow ND, Fowler JS, Gatley SJ, et al.  PET evaluation of the dopamine system of the human brain. J Nucl Med. 1996;37:1242–1256
  13. Moeller JR, Ishikawa T, Dhawan V, et al.  The metabolic topography of normal aging. J Cereb Blood Flow Metab. 1996;16:385–398
  14. Wang GJ, Volkow ND, Wolf AP, et al.  Intersubject variability of brain glucose metabolic measurements in young normal males. J Nucl Med. 1994;35:1457–1466
  15. Fowler JS, Ding YS, Volkow ND. Radiotracers for positron emission tomography imaging. Semin Nucl Med. 2003;33:14–27 (review)
  16. Volkow ND, Wang GJ, Fowler JS, et al.  Parallel loss of presynaptic and postsynaptic dopamine markers in normal aging. Ann Neurol. 1998;44:143–147
  17. Volkow ND, Logan J, Fowler JS, et al.  Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry. 2000;157:75–80
  18. Carlsson A. Brain neurotransmitters in aging and dementia. Gerontology. 1987;33:159–167
  19. Strolin Benedetti M, Dostert P. Monoamine oxidase, brain aging and degenerative diseases. Biochem Pharmacol. 1989;38:555–561
  20. Westlund KN, Denney RM, Rose RM, et al.  Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience. 1988;25:439–456
  21. Bignami A, Dahl D. Gliosis. In:  Kennmann H,  Ranson BR editor. Neuroglia. New York, NY: Oxford University Press; 1995;p. 843–858
  22. Cohen G, Kesler N. Monoamine oxidase and mitochondrial respiration. J Neurochem. 1999;73:2310–2315
  23. Fowler JS, Volkow ND, Wang G-J, et al.  Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18:431–435
  24. Eidelberg D, Moeller JR, Dhawan V, et al.  The metabolic anatomy of Parkinson’s disease (complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies). Mov Disord. 1990;5:203–213
  25. Ghaemi M, Raethjen J, Hilker R, et al.  Monosymptomatic resting tremor and Parkinson’s disease (a multitracer positron emission tomographic study). Mov Disord. 2002;17:782–788
  26. Otsuka M, Kuwabara Y, Ichiya Y, et al.  Differentiating between multiple system atrophy and Parkinson’s disease by positron emission tomography with 18F-dopa and 18F-FDG. Ann Nucl Med. 1997;11:251–257
  27. Taniwaki T, Nakagawa M, Yamada T, et al.  Cerebral metabolic changes in early multiple system atrophy (a PET study). J Neurol Sci. 2002;15:79–84
  28. Antonini A, Leenders KL, Vontobel P, et al.  Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson’s disease. Brain. 1997;120:2187–2195
  29. Kumlien E, Nilsson A, Hagberg G, et al.  PET with 11 C-deuterium-deprenyl and 18F-FDG in focal epilepsy. Acta Neurol Scand. 2001;103:360–366
  30. Small GW, Kuhl DE, Riege WH, et al.  Cerebral glucose metabolic patters in Alzheimer’s disease (effect of gender and age at dementia onset). Arch Gen Psychiatry. 1989;46:527–532
  31. Small GW, Linda ME, Silverman DHS, et al.  Cerebral metabolism and cognitive decline in persons at risk for Alzheimer’s disease. Proc Natl Acad Sci USA. 2000;97:6037–6042
  32. Agdeppa ED, Kepe V, Liu J, et al.  Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease. J Neurosci. 2001;15:RC189
  33. Shoghi-Jadid K, Small GW, Agdeppa ED, et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer’s disease. Am J Geriatric Psychiatry. 2002;10:24–35
  34. Groom GN, Lunck L, Foster NL, et al.  PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer’s disease. J Nucl Med. 1995;36:2207–2210
  35. Engler H, Lundberg PO, Ekblom K, et al.  Multitracer study with positron emission tomography in Creutzfeldt-Jacob disease. Eur J Nucl Med and Mol Imaging. 2003;30:85–95
  36. Abdel-Dayem HM, Abu-Judeh H, Kumar M, et al.  SPECT brain perfusion abnormalities in mild or moderate traumatic brain injury. Clin Nucl Med. 1998;23:309–317
  37. Newburg AB, Alavi A. Neuroimaging in patients with head trauma. In:  Freeman L editors. Nuclear Medicine Annual. Philadelphia, PA: Lippincott-Raven Publishers; 1996;p. 195–212
  38. Jossan SS, Hiraga Y, Oreland L. The cholinergic neurotoxin ethylcholine mustard aziridinium (Af64a) induces an increase in MAO B activity in the rat brain. Brain Res. 1989;476:291–297
  39. Volkow ND, Wang GJ, Maynard L, et al.  Brain dopamine is associated with eating behaviors in humans. Int J Eat Disord. 2003;33:136–142
  40. Volkow ND, Wang GJ, Fowler JS, Logan J, et al.  “Nonhedonic” food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse. 2002;44:175–180
  41. Wang GJ, Volkow ND, Logan J, et al.  Brain dopamine and obesity. Lancet. 2001;357:354–357
  42. Wang GJ, Volkow ND, Felder C, et al.  Enhanced resting activity of the oral somatosensory cortex in obese subjects. Neuroreport. 2002;13:1151–1155
  43. Ritz MC, Lamb RJ, Goldberg SR, et al.  Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science. 1987;237:1219–1223
  44. Volkow ND, Wang GJ, Fischman MW, et al.  Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature. 1997;386:827–830
  45. Volkow ND, Wang GJ, Fischman MW, et al.  Effects of route of administration on cocaine induced dopamine transporter blockade in the human brain. Life Sci. 2000;67:1507–1515
  46. Volkow ND, Fowler JS, Wang G-J, et al.  Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse. 1993;14:169–177
  47. Volkow ND, Fowler JS, Wolf AP, et al.  Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry. 1990;147:719–724
  48. Volkow ND, Fowler JS. Addiction, a disease of compulsion and drive (involvement of the orbitofrontal cortex). Cereb Cortex. 2000;10:318–325
  49. Seiden LS, Sabol KE. Methamphetamine and methylenedioxymethamphetamine neurotoxicity (possible mechanisms of cell destructions). NIDA Res Monograph. 1996;163:251–276
  50. Volkow ND, Chang L, Wang GJ, et al.  Low level of brain dopamine D2 receptors in methamphetamine abusers (association with metabolism in the orbitofrontal cortex). Am J Psychiatry. 2001;158:2015–2021
  51. Volkow ND, Fowler JS, Wang G-J. The addicted human brain (insights from imaging studies). J Clin Investigation. 2003;111:1444–1451
  52. Volkow ND, Chang L, Wang GJ, et al.  Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers. Am J Psychiatry. 2001;158:383–389
  53. Fowler JS, Volkow ND, Wang GJ, et al.  Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996;379:733–736
  54. Fowler JS, Volkow ND, Logan J. An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo. Life Sci. 1998;63:PL19–PL23
  55. Fowler JS, Logan J, Wang G-J, et al.  Monoamine oxidase and cigarette smoking. NeuroToxicology. 2002;170:1–8
  56. Khalil AA, Steyn S, Castagnoli N. Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem Res Toxicol. 2000;13:31–35
  57. George TP, Vessicchio JC, Termine A, et al.  A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003;15:136–143
  58. Volkow ND, Wang G, Fowler JS. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121
  59. Volkow ND, Fowler JS, Wang G, et al.  Mechanism of action of methylphenidate (insights from PET imaging studies). J Atten Disord. 2002;6(suppl 1):S31–S43
  60. Volkow ND, Wang G-J, Fowler JS, et al.  Effects of methylphenidate on regional brain glucose metabolism in humans (relationship to dopamine D2 receptors). Am J Psychiatry. 1997;154:50–55
  61. Mihailescu S, Drucker-Colin R. Nicotine, brain nicotinic receptors and neuropsychiatric disorders. Arch Med Res. 2000;31:131–144
  62. Nordberg A, Lilja A, Lundqvist H, et al.  Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging. 1992;13:747–758
  63. Nordberg A, Amberla K, Shigeta M, et al.  Long-term tacrine treatment in three mild Alzheimer patients (effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities). Alzheimer Dis Assoc Disord. 1998;12:228–237

PII: S0001-2998(04)00003-0

doi: 10.1053/j.semnuclmed.2004.01.002

Seminars in Nuclear Medicine
Volume 34, Issue 2 , Pages 112-121 , April 2004

Article Tools